Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATREZZO study of atezolizumab + trastuzumab + vinorelbine in pretreated HER2-positive advanced/metastatic breast cancer
2023-508829-28-00Phase 2Authorised
- Sponsor
- SOLTI
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of atezolizumab, trastuzumab and vinorelbine, sponsored by SOLTI. Planned start Jul 2024; status: authorised.
02
Drugs
Beyond the preview
Go deeper on 2023-508829-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508829-28-00.